

# Meibomian Gland Dysfunction Market Predicted to See Upsurge Through 2032, Highlights DelveInsight

*DelveInsight's Meibomian Gland Dysfunction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.*

LAS VEGAS, NV, UNITED STATES,  
January 28, 2025 /EINPresswire.com/ --

The Meibomian Gland Dysfunction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Furthermore, launching various multiple-stage Meibomian Gland Dysfunction pipeline products will significantly revolutionize the Meibomian Gland Dysfunction market dynamics.

DelveInsight's "Meibomian Gland Dysfunction Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Meibomian Gland Dysfunction, historical and forecasted epidemiology as well as the Meibomian Gland Dysfunction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Meibomian Gland Dysfunction market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Meibomian Gland Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Meibomian Gland Dysfunction Market Forecast](#)

Some of the key facts of the Meibomian Gland Dysfunction Market Report:

- The Meibomian Gland Dysfunction market size is anticipated to grow with a significant CAGR



Meibomian Gland Dysfunction Market Forecast

during the study period (2019-2032)

- In June 2024, Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company focused on creating a novel class of Ophthalmic Keratolytics for ocular surface diseases, announced the enrollment of the first patient in the ASTRO study. This Phase 3 clinical trial is designed to evaluate the efficacy and safety of AZR-MD-001 in patients exhibiting clinical signs and symptoms of Meibomian Gland Dysfunction (MGD).
- As per Sambhara et al., Meibomian Gland Dysfunction is an underdiagnosed and undertreated disease and asymptomatic Meibomian Gland Dysfunction is more common than the symptomatic Meibomian Gland Dysfunction
- Key Meibomian Gland Dysfunction Companies: Azura Ophthalmics, Novaliq, Hovione, and others
- Key Meibomian Gland Dysfunction Therapies: AZR-MD-001, NOV03, HY01, and others
- The Meibomian Gland Dysfunction epidemiology based on gender analyzed that males are more prone to Meibomian Gland Dysfunction as compared to females

### Meibomian Gland Dysfunction Overview

Meibomian gland dysfunction (MGD) is an umbrella term that encompasses several meibomian gland disorders, ranging from congenital to acquire. Disruption of Meibomian gland function negatively impacts both the quality and quantity of meibum secreted, which in turn affects ocular surface health through changes in tear film composition. Increased tear evaporation, hyperosmolarity, inflammation, and ocular surface damage can subsequently occur. This may cause discomfort, visual disruption, and sensation of dry eye.

Get a Free sample for the Meibomian Gland Dysfunction Market Report

[https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=gpr](https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr)

### Meibomian Gland Dysfunction Market

The dynamics of the Meibomian Gland Dysfunction market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“Of the emerging therapies, the most anticipated product to get launched are AZR-MD001 (Azura Ophthalmics) and NOV03 (Bausch Health Americas, Inc.). The current emerging treatment options for MGD include intraductal meibomian gland probing, emulsion eye drops containing lipids, the LipiFlow thermal pulsation system, N-acetylcysteine, azithromycin, oral supplementation with omega-3 essential fatty acids, and cyclosporine A.”

### Meibomian Gland Dysfunction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

## Meibomian Gland Dysfunction Epidemiology Segmentation:

The Meibomian Gland Dysfunction market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

- Total Prevalence of Meibomian Gland Dysfunction
- Prevalent Cases of Meibomian Gland Dysfunction by severity
- Gender-specific Prevalence of Meibomian Gland Dysfunction
- Diagnosed Cases of Episodic and Chronic Meibomian Gland Dysfunction

Download the report to understand which factors are driving Meibomian Gland Dysfunction epidemiology trends @ [Meibomian Gland Dysfunction Epidemiological Insights](#)

## Meibomian Gland Dysfunction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Meibomian Gland Dysfunction market or expected to get launched during the study period. The analysis covers Meibomian Gland Dysfunction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Meibomian Gland Dysfunction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

## Meibomian Gland Dysfunction Therapies and Key Companies

- AZR-MD-001: Azura Ophthalmics
- NOV03: Novaliq
- HY01: Hovione

## Scope of the Meibomian Gland Dysfunction Market Report

- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Meibomian Gland Dysfunction Companies: Azura Ophthalmics, Novaliq, Hovione, and others
- Key Meibomian Gland Dysfunction Therapies: AZR-MD-001, NOV03, HY01, and others
- Meibomian Gland Dysfunction Therapeutic Assessment: Meibomian Gland Dysfunction current marketed and Meibomian Gland Dysfunction emerging therapies
- Meibomian Gland Dysfunction Market Dynamics: Meibomian Gland Dysfunction market drivers and Meibomian Gland Dysfunction market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG

Matrix, Market entry strategies

- Meibomian Gland Dysfunction Unmet Needs, KOL's views, Analyst's views, Meibomian Gland Dysfunction Market Access and Reimbursement

Discover more about therapies set to grab major Meibomian Gland Dysfunction market share @ [Meibomian Gland Dysfunction Treatment Landscape](#)

## Table of Contents

1. Meibomian Gland Dysfunction Market Report Introduction
2. Executive Summary for Meibomian Gland Dysfunction
3. SWOT analysis of Meibomian Gland Dysfunction
4. Meibomian Gland Dysfunction Patient Share (%) Overview at a Glance
5. Meibomian Gland Dysfunction Market Overview at a Glance
6. Meibomian Gland Dysfunction Disease Background and Overview
7. Meibomian Gland Dysfunction Epidemiology and Patient Population
8. Country-Specific Patient Population of Meibomian Gland Dysfunction
9. Meibomian Gland Dysfunction Current Treatment and Medical Practices
10. Meibomian Gland Dysfunction Unmet Needs
11. Meibomian Gland Dysfunction Emerging Therapies
12. Meibomian Gland Dysfunction Market Outlook
13. Country-Wise Meibomian Gland Dysfunction Market Analysis (2019–2032)
14. Meibomian Gland Dysfunction Market Access and Reimbursement of Therapies
15. Meibomian Gland Dysfunction Market Drivers
16. Meibomian Gland Dysfunction Market Barriers
17. Meibomian Gland Dysfunction Appendix
18. Meibomian Gland Dysfunction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

## About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/781087054>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.